8-K: Bone Biologics Appoints Robert E. Gagnon to Board of Directors

Bone Biologics Corporation has appointed Robert E. Gagnon, a seasoned finance executive, to its Board of Directors, effective immediately.

Summary

• Bone Biologics Corporation appointed Robert E. Gagnon to its Board of Directors on January 8, 2024.
• Mr. Gagnon fills the vacancy left by Erick Lucera, who resigned on December 27, 2023.
• Mr. Gagnon will serve as chair of the audit committee and as a member of the compensation and nominating and corporate governance committees.
• He brings over 20 years of experience in finance and business operations, including roles at Gurnet Point Capital, Verastem Oncology, Harvard Bioscience, Clean Harbors, and Biogen Idec.
• Mr. Gagnon's experience includes capital raising and working with clinical stage companies, which is expected to be valuable for Bone Biologics' pilot study with NB-1.
• The company's board of directors remains at four members.

Sentiment

Score: 7

Explanation: The appointment of an experienced financial executive is a positive development, suggesting a focus on growth and stability. However, the company's status as an undercapitalized developing company introduces some uncertainty.

Positives

• The appointment of Robert E. Gagnon brings significant financial and operational expertise to the Bone Biologics board.
• Mr. Gagnon's experience in capital raising and with clinical stage companies is expected to be beneficial for the company's pilot study with NB-1.
• His background includes leadership roles at well-known companies, suggesting a high level of competence and experience.

Risks

• The company is described as an undercapitalized developing company, which may present financial challenges.
• The company's actual results may differ materially from forward-looking statements due to market conditions and other risks.
• The company's success is dependent on the outcome of its pilot study with NB-1.

Future Outlook

The company anticipates that Mr. Gagnon's experience will be valuable as they undertake their pilot study with NB-1. The company's future results are subject to various risks and uncertainties.

Management Comments

• Jeffrey Frelick, president and chief executive officer of Bone Biologics, stated that they are delighted that a professional of Rob's stature has agreed to join their board of directors.
• Mr. Frelick also mentioned that Mr. Gagnon's experiences with clinical stage companies, capital raising, and commercial organizations will be particularly valuable as they undertake their pilot study with NB-1.

Industry Context

The appointment of a seasoned finance executive like Mr. Gagnon is a positive development for a company in the orthobiologics space, particularly as they move towards clinical trials. This move aligns with the industry trend of bringing in experienced leadership to navigate the complexities of clinical development and commercialization.

Comparison to Industry Standards

• The appointment of a CFO with experience at companies like Verastem Oncology, Harvard Bioscience, and Biogen Idec is a strong move for a company like Bone Biologics, which is in a similar stage of development as these companies were at various points in their history.
• Many biotech companies at this stage seek board members with experience in capital raising, clinical trials, and commercialization, which Mr. Gagnon brings.
• His experience at Gurnet Point Capital, a healthcare venture capital and private equity fund, is also valuable as it provides insight into the investor perspective.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Mr. Gagnon positively, given his extensive experience.
• Employees may benefit from the expertise and guidance of the new board member.
• The appointment could potentially attract more investors due to the increased financial expertise on the board.

Next Steps

• Mr. Gagnon will begin his duties as a board member, including chairing the audit committee and participating in other committees.
• The company will continue to focus on its pilot study with NB-1.

Key Dates

Keywords

Board of Directors, Robert E. Gagnon, Corporate Governance, Finance, Healthcare, Biologics, Spine Fusion, Capital Raising, Clinical Stage